Recent developments in new and old viral infections

Reviews in Clinical and Experimental Hematology

Volumn 9, Issue 2, 2005, Pages

  Gentile, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CORONAVIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HERPES; HERPES VIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; INFLUENZA VIRUS; METAPNEUMOVIRUS; REVIEW; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 33744963752     PISSN: 1825151X     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant, 36: 757-769, 2005.
2. Hainsworth JD, Litchy.S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol, 21: 1746-1751, 2003.
3. Lozanski G, Heerema NA, Finn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103: 3278-3281, 2004.
4. Byrd JC, Gribben JG, Peterson BL, et al. Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. J Clin Oncol 24: 437-443, 2006.
5. Wasil T, Rai KR, Mehrotra B. The role of monoclonal antibodies in stem cell transplantation. Semin Oncol, 31: 83-99, 2004.
6. Khouri IF, Albitar M, Saliba RM, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant, 33: 833-837, 2004.
7. Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell ransplant recipients. Blood, 106: 1130-1132, 2005.
8. Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Hematol, 128: 135-144, 2004.
9. Kumar D, Humar A. Emerging viral infections in transplant recipients. Current Opinion Infect Dis, 18: 337-341, 2005.
10. Singh N. Interactions between viruses in transplant recipients. Clin Infect Dis, 40: 89-99, 2005.
11. Gentile G, Capobianchi A, Ferraironi M, et al. Relationship of serum human herpesvirus 6 DNA with cytomegalovirus pp65 antigenemia in allogeneic bone marrow transplant recipients. Transplantation, 77: 1907-1908, 2004.
12. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 343: 1378-1385, 2000.
13. Boeckh M, Leisenring W, Riddell S, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood, 101: 407-414, 2003.
14. Boeckh M, Ljungman P. Cytomegalovirus infection after BMT. In: Transplant Infections. Edited by Bowden RA, Ljungman P, Paya CV. Lippincott-Raven Publishers, Philadelphia, 215-217, 1998.
15. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes, 10: 12-16, 2003.
16. Boeckh M, Gooley TA, Meyerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomised double-blind study. Blood, 88: 4063-4071, 1996.
17. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med, 118: 173-178, 1993.
18. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood, 83: 1971-1979, 1994.
19. Junghanss C, Storb R, Maris MB, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol, 123: 662-670, 2003.
20. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99: 4357-4363, 2002.
21. Tomonari A, Iseki T, Ooi J, et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol, 121: 304-311, 2003.
22. Trenschel R, Ross S, Husing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant, 25: 665-672, 2000.
23. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 101: 3413-3415, 2003.
24. Mera JR, Whimbey E, Elting L, et al. Cytomegalovirus pneumonia in adult nontransplantation patients with cancer: review of 20 cases occurring from 1964 through 1990. Clin Infect Dis, 22: 1046-1050, 1996.
25. Broers AE, van der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood, 95: 2240-2245, 2000.
26. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood, 103: 2003-2008, 2004.
27. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood, 102: 4255-4260, 2003.
28. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis, 185: 273-282, 2002.
29. Kapasi K, Rice GP. Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness. J Virol, 62: 3603-3607, 1988.
30. Schrier RD, Oldstone MB. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis, 153: 1084-1091, 1986.
31. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol, 30: 1232-1237, 1992.
32. Gerna G, Furione M, Baldanti F, et al. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Haematol, 91: 674-683, 1995.
33. Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood, 80: 1358-1364, 1992.
34. van den Berg AP, van der Bij W, van Son WJ, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - a report of 130 consecutive patients. Transplantation, 48: 991-995, 1989.
35. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88: 4063-4071, 1996.
36. Boeckh M, Bowden RA, Gooley TA, et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood, 93: 1781-1782, 1999.
37. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev, 11: 533-554, 1998.
38. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant, 25: 765-769, 2000.
39. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 86: 2815-2820, 1995.
40. Cortez KJ, Fisher SH, Fahle GA, et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis, 188: 967-972, 2003.
41. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet, 355: 2032-2036, 2000.
42. Solano C, Munoz I, Gutierrez A, et al. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol, 39: 3938-3941, 2001.
43. Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 29: 777-782, 2002.
44. Ikewaki J, Ohtsuka E, Kawano R, et al. Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients. J Clin Microbiol, 41: 4382-4387, 2003.
45. Gerna G, Furione M, Baldanti F, Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol, 32: 2709-2717, 1994.
46. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation, 73: 968-973, 2002.
47. Limaye AP, Huang ML, Leisenring W, et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis, 183: 377-382, 2001.
48. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation, 56: 330-334, 1993.
49. Boeckh M, Gallez-Hawkins GM, Myerson D, et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation, 64: 108-113, 1997.
50. Saltzman RL, Quirk MR, Jordan MC. High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest, 90: 1832-1838, 1992.
51. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica, 89: 1248-1252, 2004.
52. Ng AP, Worth L, Chen L, et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica, 90: 1672-1679, 2005.
53. Damaj G, Charbonnier A, Bouabdallah NV, et al. Monoclonal antibodies and cytomegalovirus infections. Eur J Haematol, 73: 73-74, 2004.
54. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol, 132: 3-12, 2005.
55. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101: 4267-4272, 2003.
56. Nguyen Q, Estey E, Raad I, et al.Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis, 32: 539-545, 2001.
57. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol, 13: 2431-2448, 1995.
58. Gibbs DS, Westerman D, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol, 130: 87-91, 2005.
59. Keating Mj, Flinn L, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99: 3554-3561, 2002.
60. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chroni clymphocytic leukemia. Clin Lymphoma, 4: 220-227, 2004.
61. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood, 99: 1486-1488, 2002.
62. Anaissie EJ, Kontoyannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med, 129: 559-566, 1998.
63. Mansharami NG, Balachandran D, Vernosky I, et al. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest, 118: 712-720, 2000.
64. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet, 343: 749-753, 1994.
65. Prentice HG, Gluckman E, Powles RL, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant, 19: 129-133, 1997.
66. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood, 99: 3050-3056, 2002.
67. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med, 325: 1601-1607, 1991.
68. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med, 324: 1005-1011, 1991.
69. Emery VC, Cope AV, Bowen EF, et al. The dynamics of human cytomegalovirus replication in vivo. J Exp Med, 190: 177-182, 1999.
70. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood, 97: 867-874, 2001.
71. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 99: 1159-1164, 2002.
72. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med, 34: 111-126, 2002.
73. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood, 2005, [Epub ahead of print].
74. Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood, 101: 463-465, 2003.
75. Razonable RR, Paya C. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes, 10: 60-65, 2003.
76. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362: 1375-1377, 2003.
77. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood, 106: 4397-4406, 2005.
78. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 94: 2208-2216, 1999.
79. Au WY, Lie AK, Kwong YL, et al. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong. Leuk Lymphoma, 43: 1403-1407, 2002.
80. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Cancer Res, 159: 9-18, 2002.
81. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood, 103: 3979-3981, 2004.
82. van Esser JW, Niesters HG, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell - depleted SCT. Blood, 98: 972-978, 2001.
83. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood, 95: 1502-1505, 2000.
84. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92: 1549-1555, 1998.
85. Biasolo MA, Calistri A, Cesaro S, et al. Case report: Kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. J Med Virol, 69: 220-224, 2003.
86. Gartner BC, Fischinger J, Schafer H, et al. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease: recent results. Cancer Res, 159: 49-54, 2002.
87. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood, 107: 862-869, 2006.
88. van Esser JW, Niestars HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 99: 4364-4369, 2002.
89. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360: 436-442, 2002.
90. Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science, 234: 596-601, 1986.
91. Ablashi DV, Salahuddin SZ, Josephs SF, et al. HBLV (or HHV-6) in human cell lines. Nature, 329: 207, 1987.
92. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev, 10: 521-567, 1997.
93. Di Luca D, Mirandola P, Ravaioli T, et al. Distribution of HHV-6 variants in human tissues. Infectious Agents and Disease, 5: 203-214, 1996.
94. Kondo K, Kondo T, Okuno T, et al. Latent human herpes virus 6 infection of human monocytes/macrophages. J Gen Virol, 72:1401-1408, 1991.
95. Gentile G. Post-transplant HHV-6 Diseases. Herpes, 7: 24-27, 2000.
96. Kikuta H , Nakane A, Lu H, et al. Interferon induction by human herpesvirus 6 in human mononuclear cells. J Infect Dis, 162: 35-38, 1990.
97. Flamand L, Gosselin J, D'Addario M, et al. Human herpesvirus-6 induces interleukin 1-B and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cells cultures. J Virol, 65: 5105-5110, 1991.
98. Flamand L, Gosselin J ,Stefanescu I, et al. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood, 85: 1263-1271, 1995.
99. Drobyski WR, Dunne WM, Burd EM, et al. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow suppressive role for HHV-6 in vivo. J Infect Dis, 167: 735-739, 1993.
100. Carrigan DR, Knox KK. Human herpesvirus-6 (HHV-6) isolation from bone marrow: HHV-6 associated bone marrow suppression in bone marrow transplant patients. Blood, 84: 3307-3310, 1994.
101. Rosenfeld CS Rybka WB, Weinbaum D, et al. Late graft failure due to dual bone marrow infection with variants A and B of human herpesvirus-6. Exp Hematol, 23: 626-629, 1995.
102. Dockrell DH, Prada J, Jones MF, et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis, 176: 1135-1140, 1997.
103. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis, 178: 1783-1786, 1998.
104. Herbein G, Strasswimmer J, Altieri M, et al. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis, 22: 171-173, 1996.
105. Ogata M, Kikuchi H, Satau T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis, 193: 68-79, 2006.
106. Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis, 40: 932-940, 2005.
107. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation, 67: 399-403, 1999.
108. Yoshikawa T, Suga S, Asano Y, et al. Human herpesvirus 6 infection in bone marrow transplantation. Blood, 78: 1381-1384, 1991.
109. Kadakia MP, Rybka WB, Stewart JA, et al. Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Blood, 87: 5341-5354, 1996.
110. Ragona G, Angeloni A, Farina A, et al. Subclinical infection of the respiratory tract of immunocompromised patients by human herpesvirus -6. Blood, 85: 295-296, 1995.
111. Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus-6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med, 329: 156-161, 1993.
112. Fu-Zhang Wang, Linde A, Hagglund H, et al. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis, 28: 562-568, 1999.
113. Fu-Zhang Wang, Dahl H, Linde A, et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood, 88: 3615-3620, 1996.
114. Zerr DM, Gupta D, Yeung L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis, 33: 763-771, 2001.
115. Boutollau D, Fernadez C, Andre E, et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis, 187: 179-186, 2003.
116. Knox KK, Carrigan DR. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis, 165: 925-929, 1992.
117. Burd EM, Knox KK, Carrigan DR. Human herpesvirus -6 associated suppression of growth factor-induced maturation in human bone marrow cultures. Blood, 81: 1645-1650, 1993.
118. Drobyski WR, Eberle M, Majewski D, Baxter-Lowe LA. Prevalence of human herpesvirus 6 variant A and B in bone marrow transplant recipients as determined by polymerase chain reaction and sequence-specific oligonucleotide probe hybrization. J Clin Microbiol, 31: 1515-1520, 1993.
119. Radonic A, Oswald O, Thulke S, et al. Infections with human herpesvirus 6 variant B delay platelet engraftment after allogeneic haematopoietic stem cell transplantation. Br J Haematol, 131: 480-482, 2005.
120. Mc Cullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis, 21: 571-576, 1995.
121. Drobyski WR, Knox KK, Majeski D, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus 6 infection in a bone marrow-transplant recipient. N Engl J Med, 330: 1356-1360, 1994.
122. Gentile G, Mele A, Ragona G, et al. Human herpes virus-6 seroprevalence and leukaemias: a case-control study. GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto). Br J Cancer, 80: 1103-1106, 1999.
123. Savolainen H, Lautenschlaher I, Piiparinen H, et al. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer, 45: 820-825, 2005.
124. Dewhurst S. Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system. Herpes, 11 (Suppl. 2): 105A-111A, Review, 2004.
125. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science, 266: 1865-1869, 1994.
126. Anonymous. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC, WHO, 1997.
127. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med, 342: 1027-1038, 2000.
128. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med, 332: 1186-1191, 1995.
129. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood, 86: 1276-1280, 1995.
130. Cathomas G, Tamm M, McGandy CE, et al. Transplantation associated malignancies: restriction of human herpes virus 8 to Kaposi's sarcoma. Transplantation, 64: 175-178, 1997.
131. Bruno B, Sorasio R, Barozzi P, et al. Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation? Eur J Haematol, 2006 Jan 12, [Epub ahead of print].
132. Gentile G, Capobianchi A, Volpi A. Human herpesvirus 8 DNA in serum during seroconversion in allogeneic bone marrow transplant recipients. J Natl Cancer Inst, 97: 1008-1011, 2005.
133. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS, 17: 1717-1730, 2003.
134. Luppi M, Barozzi P, Schulz TF, et al. Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 96: 2355-2357m 2000.
135. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med, 343: 1378-1385, 2000.
136. Pastore RD, Chadburn A, Kripas C, et al. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol, 111: 1112-1115, 2000.
137. Santarelli R, Angeloni A, Farina A, et al. Lack of serologic association between human herpesvirus-8 infection and multiple myeloma and monoclonal gammopathies of undetermined significance. J Natl Cancer Inst, 90: 781-782, 1998.
138. Schulz TF. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol, 208: 187-198, 2006.
139. Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer, 88: 1-3, 2003.
140. Friedman-Birnbaum R, Weltfriend S, Pollack S. Classic Kaposi's sarcoma: T-lymphocyte subsets, T4/T8 ratio, and NK cell activity. J Am Acad Dermatol, 24: 937-940, 1991.
141. Martin JN. Diagnosis and epidemiology of human herpesvirus 8 infection. Semin Hematol, 40: 133-142, 2003.
142. Cottoni F, Santarelli R, Gentile G, et al. High rate of human herpesvirus-8 seroprevalence in thalassemic patients in Italy. J Clin Virol, 30: 106-109, 2004.
143. Mbulaiteye SM, Biggar RJ, Bakaki PM, et al. Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda. J Natl Cancer Inst, 95: 1330-1335, 2003.
144. Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med, 9: 554-561, 2003.
145. Coluzzi M, Calabrò ML, Manno D, et al. Saliva and the transmission of human herpesvirus 8: potential role of promoter-arthropod bites. J Infect Dis, 190: 199-200, 2004.
146. Andreoni M, Sarmati L, Nicastri E, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA, 287: 1295-1300, 2002.
147. Wang QJ, Jenkins FJ, jacobson LP, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood, 97: 2366-2373, 2001.
148. Dagna L, Broccolo F, Paties CT, et al. A relapsing inflammatory syndrome and active human herpesvirus 8 infection. N Engl J Med, 353: 156-163, 2005.
149. Edelman DC. Human herpesvirus 8 - a novel human pathogen. Virol J, 2: 78, 2005.
150. Rabkin CS, Schultz TF, Whitby D, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis, 178: 304-309, 1998.
151. . Spira Tj, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol, 38: 2174-2180, 2000.
152. Camera Pierrotti L, Masami Sumita L, Santos Freire W, et al. Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi's sarcoma. J Clin Virol, 16: 247-251, 2000.
153. Goudsmith J, Ranwick N, Dukers NH, et al. Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73. Proc Natl Acad Sci USA, 97: 4838-4843, 2000.
154. Mendez JC, Procop GW, Espy MJ, et al. Relationship of HHV-8 replication and Kaposi's sarcoma after solid organ transplantation. Transplantation, 67: 1200-1201, 1999.
155. Cannon MJ, Laney AS, Pellet PE. Human herpesvirus 8: current issues. Clin Infect Dis, 37: 82-87, 2003.
156. Michaels MG, Jenkins FJ. Human herpesvirus 8: Is it time for routine surveillance in pediatric solid organ transplant recipients to prevent the development of Kaposi's sarcoma? Pediatr Transplant, 7: 1-3, 2003.
157. Mazzi R, Parisi SG, sarmati L, et al. fficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS, 15: 2061-2062, 2001.
158. Camper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood, 103: 1632-1634, 2004.
159. Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant, 7 (Suppl.): 2S-4S, 2001.
160. Wingard JR, Nichols WG, McDonald GB. Supportive care. Hematology (Am Soc Hematol Educ Program), 372-389, Review, 2004.
161. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis, 39: 1300-1306, 2004.
162. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood, 98: 573-578, 2001.
163. Raboni S, Nogueria MB, Tsuchya LRV, et al. Respiratory tract viral infections in bone marrow transplant recipients. Transplantation, 76: 142-146, 2003.
164. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplants recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Hematol, 119: 1125-1132, 2002.
165. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant, 31: 695-700, 2003.
166. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis, 165: 987-993, 1992.
167. Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis, 184: 350-354, 2001.
168. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med, 7: 719-724, 2001.
169. Fouchier RA, Rimmelzwaan GF, Kuiken T, et al. Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human coronaviruses. Curr Opin Infect Dis, 18: 141-146, 2005.
170. Hamelin ME, Boivin G. Human metapneumovirus: a ubiquitous and
171. Pelletier G, De'ry P, Abed Y, et al. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis, 8: 976-978, 2002.
172. Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis, 42: 518-524, 2006.
173. Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Medicine, 10: S88-S97, 2004.
174. Kumar D, Humar A. Emerging viral infections in transplant recipients. Curr Opin Infect Dis, 18: 337-341, 2005.
175. Ison MG, Hayden FG. Viral infections in immunocompromised patients:what's new with respiratory viruses? Curr Opin Infect Dis, 15: 355-367, 2002.
176. Machado CM, Cardoso MR, da Rocha IF, et al. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant, 36: 897-900, 2005.
177. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant infuenza virus from immunocompromsed patients: a case series. J Infect Dis, 193: 760-764, 2006.